High presence of molecule microRNA 451 improves chances of survival for stomach cancer patients, new study reveals.
Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra presented the findings at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.
Advertisement
Pharmacogenetics studies the genetic bases determining the response of an individual to treatment, as well as possible toxic reactions; pharmacogenomics analyses the molecular and biological mechanisms involved in a disease in order to develop new medicines. "We know that variations in small molecules (microRNAs) give rise to different responses to the same pharmaceutical drug. In this line, a number of approaches are being made in clinical practice, such as the study of mutations of the K-RAS gene in cancer of the colon or of the EGFR in lung cancer, and which enable directing individualised treatment for each patient".
The study presented at this scientific meeting analysed the role of microRNA 451 in stomach cancer, "Patients with a high expression of this molecule show greater survival rates, and so could be a biomarker for treatment response". The CIMA researchers are also taking part in other trials, such as studies with the 192 and 215 microRNAs, which influence the response to pharmaceutical drugs against cancer of the colon, at the preclinical phase.
Besides its application in cancer, pharmacogenetics is demonstrating its efficacy in other disciplines such as psychiatry as also in the treatment of cardiovascular diseases. "One of the great risks of these illnesses is controlling the thrombotic processes involved in cerebrovascular accidents. The study of certain genes, such as ALOX5AP, can direct the most appropriate medication for each patient", explained Dr. García-Foncillas.
In the opinion of the CIMA researcher, "the convergence of genetic and pharmacological studies has created a way for optimising both the treatment for each patient as well as health resources, given that we will be able to use pharmaceutical drugs in suitable doses, with fewer side effects and with patients that show better therapeutic response".
Source: Medindia
Advertisement
Besides its application in cancer, pharmacogenetics is demonstrating its efficacy in other disciplines such as psychiatry as also in the treatment of cardiovascular diseases. "One of the great risks of these illnesses is controlling the thrombotic processes involved in cerebrovascular accidents. The study of certain genes, such as ALOX5AP, can direct the most appropriate medication for each patient", explained Dr. García-Foncillas.
In the opinion of the CIMA researcher, "the convergence of genetic and pharmacological studies has created a way for optimising both the treatment for each patient as well as health resources, given that we will be able to use pharmaceutical drugs in suitable doses, with fewer side effects and with patients that show better therapeutic response".
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Brain plasticity following blindness leads to superior ability in sensing signals from the heart, which has implications for bodily awareness and emotional processing.
A group of scientists were awarded Ł1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.
Is there a connection between Osteoporosis and dementia? Yes, loss in bone density may be linked to an increased risk of dementia in older age.
Link between chromosome length and biological aging marker discovered. The finding helps explain why people with longer telomeres have a lower dementia risk.
Integrated structural biology helps discover how the cystic fibrosis transmembrane conductance regulator (CFTR) works.